Leal, Lorna http://orcid.org/0000-0001-7887-6027
Pich, Judit
Ferrer, Laura
Nava, Jocelyn
Martí-Lluch, Ruth http://orcid.org/0000-0002-7320-9521
Esteban, Ignasi
Pradenas, Edwards http://orcid.org/0000-0001-5162-8920
Raïch-Regué, Dàlia http://orcid.org/0000-0001-7656-5700
Prenafeta, Antoni
Escobar, Karla
Pastor, Carmen
Ribas-Aulinas, Marc http://orcid.org/0000-0002-8214-6155
Trinitè, Benjamin http://orcid.org/0000-0003-3809-042X
Muñoz-Basagoiti, Jordana
Domenech, Gemma
Clotet, Bonaventura
Corominas, Júlia
Corpes-Comes, Aida
Garriga, Carme
Barreiro, Antonio
Izquierdo-Useros, Nuria http://orcid.org/0000-0002-1039-1821
Arnaiz, Joan Albert
Soriano, Alex
Ríos, José http://orcid.org/0000-0002-0716-8784
Nadal, Marga
Plana, Montserrat
Blanco, Julià http://orcid.org/0000-0002-2225-0217
Prat, Teresa
Torroella, Elia
Ramos, Rafel
Bonfill, Eva
Anagua, Omar
Caicedo, Faisury
Castán, Clara
Guazina, Fauno
Messeguer, Sara
Aldea, Marta
Vilella, Anna
Serrano, Sandra
Leal, Lorna
Pich, Judit
Nava, Jocelyn
Escobar, Karla
Arnaiz, Joan Albert
Soriano, Alex
Ríos, José
Botta, Teresa
Esteban, Ignasi
Pastor, Carmen
Plana, Montserrat
Domenech, Gemma
Marfil, Silvia
Rovirosa, Carla
Ortiz, Raquel
Perez-Zsolt, Daniel
Gallemí, Marçal
Pradenas, Edwards
Raïch-Regué, Dàlia
Trinité, Benjamin
Muñoz-Basagoiti, Jordana
Clotet, Bonaventura
Izquierdo-Useros, Nuria
Blanco, Julià
González del Río, Marina
Martí-Lluch, Ruth
Ribas-Aulinas, Marc
Corpes-Comes, Aida
Nadal, Marga
Ramos, Rafel
González, Luís
Cañete, Manuel
Madrenas, Laia
Moros, Alexandra
Güell, Irina
Ferrer, Laura
Prenafeta, Antoni
Corominas, Júlia
Garriga, Carme
Barreiro, Antonio
Prat, Teresa
Torroella, Elia
,
Funding for this research was provided by:
HIPRA, Avenida la Selva 135 Amer, Spain
Hipra, Avenida la Selva
Hipra, La selva
Hipra, La Selva
Article History
Received: 23 October 2022
Accepted: 15 September 2023
First Online: 29 September 2023
Competing interests
: L.L. has received consulting fees from HIPRA, not related to this work and has received institutional grants from HIPRA, AstraZeneca B.V. and Janssen Pharmaceuticals Companies of Johnson & Johnson. A.S. has received grants from Pfizer and Gilead Sciences and honoraria for lectures for Pfizer, MSD, Gilead Sciences, Shionogi, Angelini, Roche and Menarini. J.R. has received educational/training fees from AstraZeneca, Boehringer Ingelheim, Janssen-Cilag, MSD España S.A., Novartis, LETI Pharma and Lilly. J.B. has received institutional grants from HIPRA, Grifols, Nesapor Europe and MSD; outside of this work is CEO and founder of AlbaJuna Therapeutics, S.L. NIU has received institutional grants from HIPRA, Grifols, Dentaid, Pharma Mar, Palobiofarma, and Amassence. L.F., A.P., C.G., A.B., J.C., T.P., and E.T. are employed by the Sponsor, HIPRA and some may have stocks. All other authors declare no competing interests.